{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:57:44Z","timestamp":1793735864864,"version":"4.6.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.pharmthera.2019.05.013","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T22:13:32Z","timestamp":1559686412000},"page":"53-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Cognitive dysfunction in major depression: From assessment to novel therapies"],"prefix":"10.1016","volume":"202","author":[{"given":"Hafsa","family":"Atique-Ur-Rehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.05.013_bb0005","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/0269881111424928","article-title":"Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals","volume":"26","author":"Antypa","year":"2012","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nutres.2017.10.013","article-title":"Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression","volume":"50","author":"Bae","year":"2018","journal-title":"Nutrition Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jad.2018.01.027","article-title":"Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales","volume":"231","author":"Ballard","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jad.2017.08.080","article-title":"Cognition in depression: Can we THINC-it better?","volume":"225","author":"Baune","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.psychres.2008.12.001","article-title":"The role of cognitive impairment in general functioning in major depression","volume":"176","author":"Baune","year":"2010","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.euroneuro.2013.11.001","article-title":"Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder","volume":"24","author":"Belgaied","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0035","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1017\/S0033291717000113","article-title":"Impact of deep brain stimulation of the ventral anterior limb of the internal capsule on cognition in depression","volume":"47","author":"Bergfeld","year":"2017","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jad.2011.03.049","article-title":"Gray matter abnormalities in major depressive disorder: A meta-analysis of voxel based morphometry studies","volume":"138","author":"Bora","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0045","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1017\/S0033291712002085","article-title":"Cognitive impairment in euthymic major depressive disorder: A meta-analysis","volume":"43","author":"Bora","year":"2013","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0050","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2174\/1871527313666141130203823","article-title":"Cognitive dysfunction in major depressive disorder: A state-of-the-art clinical review","volume":"13","author":"Bortolato","year":"2014","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0055","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/NMD.0b013e31829c5030","article-title":"Cognitive remediation for treatment-resistant depression: Effects on cognition and functioning and the role of online homework","volume":"201","author":"Bowie","year":"2013","journal-title":"The Journal of Nervous and Mental Disease"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/acps.12690","article-title":"A systematic review of cognitive effects of exercise in depression","volume":"135","author":"Brondino","year":"2017","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pnpbp.2017.04.023","article-title":"Depressive disorders: Processes leading to neurogeneration and potential novel treatments","volume":"80","author":"Brown","year":"2018","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cpr.2018.07.005","article-title":"Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis","volume":"64","author":"Buckman","year":"2018","journal-title":"Clinical Psychology Review"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0075","first-page":"1","article-title":"Effects of physical activity on cognitive performance: A controlled clinical study in depressive patients","author":"Buschert","year":"2018","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.psychres.2018.08.033","article-title":"The clinical relationship between cognitive impairment and psychosocial functioning in major depressive disorder: A systematic review","volume":"269","author":"Cambridge","year":"2018","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0085","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2174\/1871527313666141130203627","article-title":"Cognitive dysfunction in depression - pathophysiology and novel targets","volume":"13","author":"Carvalho","year":"2014","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jad.2017.06.036","article-title":"Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder","volume":"222","author":"Cha","year":"2017","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbi.2011.07.239","article-title":"Treatment response and cognitive impairment in major depression: Association with C-reactive protein","volume":"26","author":"Chang","year":"2012","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2018.07.033","article-title":"Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion","volume":"241","author":"Chen","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14737167.2016.1195688","article-title":"Cognitive dysfunction and work productivity in major depressive disorder","volume":"16","author":"Clark","year":"2016","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0110","unstructured":"Cogstate. Cognigram detects cognitive impairment in schizophrenia patients. [ONLINE]. Available from: https:\/\/www.cogstate.com\/cognigram-detects-cognitive-impairment-schizophrenia-patients [Accessed 8 December 2018], 2014."},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/JGP.0b013e3181b4bf4a","article-title":"Change in cognitive functioning following acute antidepressant treatment in late-life depression","volume":"17","author":"Culang","year":"2009","journal-title":"The American Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/gps.2783","article-title":"Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline","volume":"27","author":"Culang-Reinlieb","year":"2012","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1871527314666150821103825","article-title":"A comprehensive review on the efficacy of S-Adenosyl-L-methionine in major depressive disorder","volume":"15","author":"De Berardis","year":"2016","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.jcp.0000104910.75206.b9","article-title":"A prospective trial of modafinil as an adjunctive treatment of major depression","volume":"24","author":"DeBattista","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neubiorev.2018.09.006","article-title":"The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation","volume":"94","author":"Dooley","year":"2018","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0140","doi-asserted-by":"crossref","first-page":"M1137","DOI":"10.1093\/gerona\/58.12.M1137","article-title":"Does antidepressant therapy improve cognition in elderly depressed patients?","volume":"58","author":"Doraiswamy","year":"2003","journal-title":"The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13063-018-2829-7","article-title":"Anti-inflammatory treatment of depression: Study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo","volume":"19","author":"Fourrier","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pnpbp.2017.03.016","article-title":"The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs","volume":"80","author":"Galecki","year":"2018","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0165","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neubiorev.2017.08.018","article-title":"Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression","volume":"84","author":"Gandelman","year":"2018","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jad.2017.09.041","article-title":"Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials","volume":"226","author":"Giacobbe","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0175","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.psychres.2014.12.004","article-title":"Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: Paroxetine vs. bupropion","volume":"225","author":"Gorlyn","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.genhosppsych.2017.06.002","article-title":"Evaluation of the benefits of exercise on cognition in major depressive disorder","volume":"49","author":"Greer","year":"2017","journal-title":"General Hospital Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0190","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/1440-1681.12265","article-title":"Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus","volume":"41","author":"Guo","year":"2014","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.05.013_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw054","article-title":"Which cognitive domains are improved by treatment with Vortioxetine?","volume":"19","author":"Harrison","year":"2016","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2010.11.011","article-title":"Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review","volume":"134","author":"Hasselbalch","year":"2011","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.psyneuen.2018.02.032","article-title":"Longitudinal associations between biomarkers of inflammation and changes in depressive symptoms in patients with type 1 and type 2 diabetes","volume":"91","author":"Herder","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jad.2009.10.009","article-title":"Major depressive disorder in recovery and neuropsychological functioning: Effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery","volume":"123","author":"Herrera-Guzman","year":"2010","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0215","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jpsychires.2008.10.015","article-title":"Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder","volume":"43","author":"Herrera-Guzman","year":"2009","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.psychres.2005.11.011","article-title":"Neurocognitive deficits and disability in major depressive disorder","volume":"145","author":"Jaeger","year":"2006","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0225","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpsychires.2018.09.016","article-title":"Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders - results from a double-blind, randomized and placebo-controlled clinical trial","volume":"107","author":"Jahangard","year":"2018","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bpsc.2016.11.009","article-title":"Modafinil improves episodic memory and working memory cognition in patients with remitted depression: A double-blind, randomized, placebo-controlled study","volume":"2","author":"Kaser","year":"2017","journal-title":"Biological Psychiatry. Cognitive Neuroscience and Neuroimaging"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2019.05.013_bb0240","first-page":"1","article-title":"The longitudinal course of cognitive impairment in schizophrenia: An examination of data from premorbid through post-treatment phases of illness","volume":"75","author":"Keefe","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0245","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2215-0366(16)00095-X","article-title":"Treating cognitive impairment in depression: An unmet need","volume":"3","author":"Keefe","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0250","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4088\/JCP.13r08609","article-title":"Cognitive effects of pharmacotherapy for major depressive disorder: A systematic review","volume":"75","author":"Keefe","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0255","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jad.2018.08.034","article-title":"The lack of meaningful association between depression severity measures and neurocognitive performance","volume":"241","author":"Keilp","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0260","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jad.2018.04.051","article-title":"The role of cognitive impairment in psychosocial functioning in remitted depression","volume":"235","author":"Knight","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0265","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3389\/fpsyt.2018.00309","article-title":"Executive subdomains are differentially associated with psychosocial outcomes in major depressive disorder","volume":"9","author":"Knight","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0270","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jnnp-2016-313803","article-title":"Cognitive outcome after ventral capsule\/ventral striatum stimulation for treatment-resistant major depression","volume":"88","author":"Kubu","year":"2017","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0275","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.2014.14070889","article-title":"Citalopram, methylphenidate, or their combination in geriatric depression: A randomized, double-blind, placebo-controlled trial","volume":"172","author":"Lavretsky","year":"2015","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0280","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jad.2011.10.023","article-title":"A meta-analysis of cognitive deficits in first-episode major depressive disorder","volume":"140","author":"Lee","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0285","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cpr.2018.06.008","article-title":"Depression: A cognitive perspective","volume":"69","author":"LeMoult","year":"2019","journal-title":"Clinical Psycology Review"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0290","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jad.2011.04.059","article-title":"Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder","volume":"136","author":"Levkovitz","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0300","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1055\/s-0043-114670","article-title":"Erythropoietin for cognitive deficits associated with schizophrenia, bipolar disorder, and major depression: A systematic review","volume":"51","author":"Li","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000492620","article-title":"Cognitive impairment along the course of depression: Non-pharmacological treatment options","volume":"51","author":"Listunova","year":"2018","journal-title":"Psychopathology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0310","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1176\/ajp.2007.164.5.823","article-title":"White matter abnormalities in first-episode, treatment-naive young adults with major depressive disorder","volume":"164","author":"Ma","year":"2007","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0315","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/npp.2013.334","article-title":"Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder","volume":"39","author":"Madhoo","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0320","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/npp.2015.52","article-title":"A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of Vortioxetine on cognitive function in major depressive disorder","volume":"40","author":"Mahableshwarkar","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2004.09.010","article-title":"Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia","volume":"72","author":"Marder","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neubiorev.2018.04.008","article-title":"Cognitive effects of transcranial direct current stimulation treatment in patients with major depressive disorder: An individual patient data meta-analysis of randomised, sham-controlled trials","volume":"90","author":"Martin","year":"2018","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0335","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/00325481.2016.1221318","article-title":"The impact of cognitive challenges in major depression: The role of the primary care physician","volume":"128","author":"Mattingly","year":"2016","journal-title":"Postgraduate Medicine"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0340","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s00213-018-5019-0","article-title":"The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose","volume":"235","author":"McGlashan","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0345","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4088\/JCP.16m11329","article-title":"The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: Validation in patients with major depressive disorder","volume":"78","author":"McIntyre","year":"2017","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0350","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/JCP.0000000000000723","article-title":"The efficacy of psychostimulants in major depressive episodes: A systematic review and meta-analysis","volume":"37","author":"McIntyre","year":"2017","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0355","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0360","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-010-1842-7","article-title":"Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients","volume":"210","author":"Miskowiak","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0365","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.euroneuro.2016.09.641","article-title":"Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field","volume":"26","author":"Miskowiak","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0370","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/npp.2013.335","article-title":"Recombinant human erythropoietin for treating treatment-resistant depression: A double-blind, randomized, placebo-controlled phase 2 trial","volume":"39","author":"Miskowiak","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0375","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jad.2015.09.022","article-title":"Computerized cognitive training and functional recovery in major depressive disorder: A meta-analysis","volume":"189","author":"Motter","year":"2016","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0380","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/npp.2014.298","article-title":"Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: A randomized controlled trial","volume":"40","author":"Murrough","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0385","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpsycho.2018.07.004","article-title":"Enhanced theta-gamma coupling associated with hippocampal volume increase following high-frequency left prefrontal repetitive transcranial magnetic stimulation in patients with major depression","volume":"133","author":"Noda","year":"2018","journal-title":"International Journal of Psychophysiology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0390","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.euroneuro.2016.05.009","article-title":"The effect of erythropoietin on cognition in affective disorders - associations with baseline deficits and change in subjective cognitive complaints","volume":"26","author":"Ott","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.genhosppsych.2003.07.004","article-title":"Quality of life assessments in major depressive disorder: A review of the literature","volume":"26","author":"Papakostas","year":"2004","journal-title":"General Hospital Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0400","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.euroneuro.2017.04.001","article-title":"Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation","volume":"27","author":"Pariante","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0405","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.psychres.2008.06.042","article-title":"Cognitive deficits in the euthymic phase of unipolar depression","volume":"169","author":"Preiss","year":"2009","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0410","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/mp.2015.22","article-title":"Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: A proof-of-concept study","volume":"21","author":"Rapaport","year":"2016","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0415","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/ajp.2007.164.6.900","article-title":"Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial","volume":"164","author":"Raskin","year":"2007","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0420","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/0269881116631649","article-title":"The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: A substudy of a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Reddy","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0425","first-page":"1","article-title":"A new generation computerised metacognitive cognitive remediation programme for schizophrenia (CIRCuiTS): A randomised controlled trial","author":"Reeder","year":"2017","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0430","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/wps.20050","article-title":"The DSM-5: Classification and criteria changes","volume":"12","author":"Regier","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0435","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1177\/0269881117722998","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy","volume":"31","author":"Richards","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0440","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1017\/S0033291713002535","article-title":"Cognitive impairment in depression: A systematic review and meta-analysis","volume":"44","author":"Rock","year":"2014","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0445","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S0007114507801097","article-title":"No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial","volume":"99","author":"Rogers","year":"2008","journal-title":"The British Journal of Nutrition"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0455","article-title":"The cognitive effects of antidepressants in major depressive disorder: A systematic review and meta-analysis of randomized clinical trials","volume":"19","author":"Rosenblat","year":"2015","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0460","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.rpsm.2017.06.006","article-title":"Vortioxetine: A new alternative for the treatment of major depressive disorder","volume":"11","author":"Salagre","year":"2018","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0465","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jad.2017.06.034","article-title":"Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives","volume":"221","author":"Salagre","year":"2017","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0470","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jad.2016.12.036","article-title":"Cognitive control dysfunction in emotion dysregulation and psychopathology of major depression (MD): Evidence from transcranial brain stimulation of the dorsolateral prefrontal cortex (DLPFC)","volume":"210","author":"Salehinejad","year":"2017","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0475","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0480","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.euroneuro.2018.07.098","article-title":"Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial","volume":"28","author":"Sarris","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0485","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13063-018-2627-2","article-title":"Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: A study protocol for a randomized controlled trial","volume":"19","author":"Schmidt","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0490","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fpsyt.2018.00337","article-title":"Neural and behavioral predictors of treatment efficacy on mood symptoms and cognition in mood disorders: A systematic review","volume":"9","author":"Seeberg","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0495","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2215-0366(16)00012-2","article-title":"Effect of antidepressant treatment on cognitive impairments associated with depression: A randomised longitudinal study","volume":"3","author":"Shilyansky","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0500","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S1461145714001011","article-title":"Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression","volume":"17","author":"Shiroma","year":"2014","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0505","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/mp.2017.104","article-title":"Vortioxetine reduces BOLD signal during performance of the N-back working memory task: A randomised neuroimaging trial in remitted depressed patients and healthy controls","volume":"23","author":"Smith","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0510","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.psychres.2014.06.053","article-title":"The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial","volume":"220","author":"Soczynska","year":"2014","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0515","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euroneuro.2014.12.004","article-title":"Cognition as a target in major depression: New developments","volume":"25","author":"Sole","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0520","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jpsychires.2015.04.024","article-title":"Changes in cognitive symptoms after a buspirone-melatonin combination treatment for major depressive disorder","volume":"68","author":"Targum","year":"2015","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0525","doi-asserted-by":"crossref","first-page":"28028","DOI":"10.1038\/srep28028","article-title":"Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder","volume":"6","author":"Tian","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0530","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0004867415622271","article-title":"Cognitive remediation for depressed inpatients: Results of a pilot randomized controlled trial","volume":"50","author":"Trapp","year":"2016","journal-title":"The Australian and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0535","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881104042622","volume":"18","author":"Trick","year":"2004","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0545","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euroneuro.2018.02.001","article-title":"Cognitive predictors of illness course at 12 months after first-episode of depression","volume":"28","author":"Vicent-Gil","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0550","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jad.2017.11.053","article-title":"The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram","volume":"227","author":"Vieta","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.05.013_bb0555","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/YCT.0b013e3182a4b4c6","article-title":"Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: A randomized, double-blind study","volume":"30","author":"Yoosefi","year":"2014","journal-title":"The Journal of ECT"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819300968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819300968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:58:08Z","timestamp":1759010288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819300968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":105,"alternative-id":["S0163725819300968"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.05.013","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive dysfunction in major depression: From assessment to novel therapies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}